Table 1.
Comparison between AChR+ generalized MG patients with and without eculizumab treatment.
| With eculizumab n = 36 | Without eculizumab n = 1070 | p value | |
|---|---|---|---|
| Age (years) | 56.0 ± 17.0 | 61.7 ± 16.1 | 0.053 |
| Female | 28 (78%) | 670 (63%) | 0.640 |
| Disease duration (years) | 11.3 ± 9.0 | 12.6 ± 10.7 | 0.557 |
| MG subtype | |||
| Early onset | 13 (36%) | 352 (33%) | 0.687 |
| Late‐onset | 7 (19%) | 344 (32%) | 0.107 |
| Thymoma‐associated | 16 (44%) | 374 (35%) | 0.241 |
| Worst MGFA classification | |||
| II (mild) | 1 (3%) | 601 (56%) | <0.01 |
| III (moderate) | 13 (36%) | 274 (26%) | 0.157 |
| IV (severe) | 10 (28%) | 60 (6%) | <0.01 |
| V (crisis) | 12 (33%) | 104 (10%) | <0.01 |
| Worst quantitative MG | 21.6 ± 8.7 | 14.2 ± 6.3 | <0.01 |
| Immunosuppressive therapy | |||
| Oral prednisolone | 36 (100%) | 725 (68%) | <0.01 |
| Calcineurin inhibitors | 35 (97%) | 668 (62%) | <0.01 |
| Thymectomy | |||
| Thymectomy for thymoma | 16/16 (100%) | 362/365 (99%) | 0.716 |
| Thymectomy for non‐thymoma | 6/20 (30%) | 276/705 (39%) | 0.408 |
| Fast‐acting treatment | |||
| Plasmapheresis | 34 (94%) | 276 (26%) | <0.01 |
| Intravenous immunoglobulin | 33 (92%) | 305 (29%) | <0.01 |
| Intravenous high‐dose methylprednisolone | 35 (97%) | 450 (42%) | <0.01 |
| Refractory | 33 (92%) | 197 (18%) | <0.01 |
AChR+, anti‐acetylcholine receptor‐positive; MG, myasthenia gravis; MGFA, MG Foundation of America.